Article information
Full text is only aviable in PDF
References
[1.]
C.M. Meyers, L.B. Seeff, C.O. Stehman-Breen, J.H. Hoofnagle.
Hepatitis C and renal disease: An update.
Am J Kidney Dis, 42 (2003), pp. 631-657
[2.]
C. Ferri, M. Sebastinani, D. Giuggioli, M. Cazzato, G. Longombardo, A. Antonelli, et al.
Mixed cryoglobulinaemia: Demographic, clinical, and serologic features and survival in 231 patients.
Semin Arthritis Rheum, 33 (2004), pp. 355-374
[3.]
M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, J. Font.
Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection.
Rheumatology, 42 (2003), pp. 818-828
[4.]
N. Kamar, L. Rostaing, R. Arlic.
Treatment of hepatitis C-virus-related glomerulonephritis.
Kidney Int, 69 (2006), pp. 436-439
[5.]
F. Zaja, S. de Vita, C. Mazzaro, S. Sacco, D. Damiani, G. de Marchi, et al.
Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Blood, 101 (2003), pp. 3827-3834
[6.]
D. Rocatello, S. Baldovino, D. Rossi, M. Mansouiri, C. Naretto, M. Gennaro, et al.
Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
Nephrol Dial Transplant, 19 (2004), pp. 3054-3061
[7.]
L. Quartuccio, G. Soardo, G. Romano, F. Zaja, C.A. Scott, G. de Marchi, et al.
Rituximab treatment for glomelulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the abscense of steroids.
Rheumatology, 45 (2006), pp. 842-846
[9.]
D. Sansono, V. de Re, G. Lauletta, F.A. Tucci, M. Boiocchi, F. Dammacco.
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon a with an anti-CD20.
Blood, 101 (2003), pp. 3818-3826
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
